Effects of histaminergic antagonists on the GH-releasing activity of GHRH or hexarelin, a synthetic hexapeptide, in man

Journal of Endocrinological Investigation

Volumn 20, Issue 3, 1997, Pages 122-127

  Arvat, E ^a   Maccagno, B ^a   Ramunni, J ^a   Gianotti, L ^a   Di Vito, L ^a   Deghenghi, R ^b   Camanni, F ^a   Ghigo, E ^a,c  

^a UNIVERSITY OF TURIN   (Italy)

^b Ardana   (France)

^c Divisione di Endocrinologia OIRM Torino   (Italy)

Author keywords

ACTH; Cortisol; GH; GHRH; Hexarelin; Histamine; PRL

Indexed keywords

ANTIHISTAMINIC AGENT; CORTICOTROPIN; DIPHENHYDRAMINE; GROWTH HORMONE; GROWTH HORMONE RELEASING FACTOR; HEXARELIN; HISTAMINE; HISTAMINE H1 RECEPTOR; HYDROCORTISONE; PROLACTIN; SERMORELIN; TERFENADINE;

ADULT; ANTICHOLINERGIC EFFECT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CORTICOTROPIN BLOOD LEVEL; CORTICOTROPIN RELEASE; FEMALE; FOLLICULAR PHASE; GROWTH HORMONE RELEASE; HUMAN; HUMAN EXPERIMENT; HYDROCORTISONE BLOOD LEVEL; HYDROCORTISONE RELEASE; INTRAVENOUS DRUG ADMINISTRATION; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PROLACTIN BLOOD LEVEL;

EID: 0030991479     PISSN: 03914097     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03346889     Document Type: Article

References (33)

1. Ghigo E. Neurotransmitter control of growth hormone secretion. In: De la Cruz L.F. (Ed.), Regulation of growth hormone and somatic growth. Excerpta Medica, Amsterdam, 1992, p. 103.
2. Müller E.E., Nisticò G. Neurotransmitter regulation of the anterior pituitary. In: Müller E.E., Nisticò G. (Eds.), Brain Messengers and the Pituitary. Academic Press, Inc., San Diego, 1989, p. 404.
3. Casanueva F.F. Physiology of growth hormone secretion and action. In: Melmed S. (Ed.), Endocrinology and Metabolism Clinics of North America. Saunders Company, Philadelphia, 1992, p. 483.
4. Pontiroli A.E., Viberti G., Vicari A., Pozza G. Effects of the antihistamine agents meclastine and chlorpheniramine on the response of human GH to arginine infusion and insulin-hypoglycemia. Clin. Endocrinol. Metab. 3: 582, 1976.
5. Penalva A., Villanueva L., Casanueva F.F., Cavagnini F., Gomez Pan A., Müller E.E. Cholinergic and histaminergic involvement in growth hormone releasing effect of an enkephalin analogue (FK33-824). Psychopharmacology 80: 120, 1983.
6. Pontiroli A.E., Pellicciotta G., Alberetto M., DeCastro e Silva E., DePasqua A., Girardi A.M., Pozza G. Repeated cimetidine administration reduces the Growth Hormone (GH) response to insulin-hypoglycemia. Horm. Metab. Res. 12: 172,1980.
7. Valk T.W., England B.G., Marshall J.C. Effects of cimetidine on pituitary function: alteration in hormone secretion profiles. Clin. Endocrinol. (Oxf.) 15: 139, 1981.
8. Knigge U., Dejgaard A., Wollesen F., Thuesen B., Christiansen P.M. Histamine regulation of prolactin secretion through H1 and H2 histamine receptors. J. Clin. Endocrinol. Metab. 55: 118, 1982.
9. Knigge U., Warberg J. The role of histamine in the neuroendocrine regulation of pituitary hormone secretion. Acta Endocrinol. (Copenh) 124: 609, 1991.
10. Carlson H.E., Ippoliti A.F. Cimetidine, an H2-antihistamine, stimulates prolactin secretion in man. Clin. Endocrinol. Metab. 45: 367, 1977.
11. Burland W.L., Gleadle R.I., Lee R.M., Rowley J.D. Cimetidine and serum prolactin. Br. Med. J. 1: 717, 1978.
12. Nelis G.F., Van de Maen J.G.C. Comparative effects of cimetidine and ranitidine on prolactin secretion. Postgrad. Med. J. 56: 478, 1980.
13. Allolio B., Winkelmann W., Hipp F.X. Effect of meclastine, an H-1 antihistamine, on plasma ACTH in adrenal insufficiency. Acta Endocrinol. (Copenh.) 97: 98, 1981.
14. Allolio B., Deuss U., Kaulen D., Winkelmann W. Effects of meclastine, a selective H1 receptor antagonist, upon ACTH release. Clin. Endocrinol. (Oxf.) 19: 239, 1983
15. Ghigo E., Arvat E., Gianotti L., Grottoli S., Rizzi G., Ceda G.P., Deghenghi R., Camanni F. Aging and GH-releasing peptides. In: Bercu B., Walker R. (Eds.), Growth hormone secretagogues. Serono Symposia, New York, 1996, p. 415.
16. Bowers C.Y., Veeraragavan K., Sethumadahavan K. Atipical growth hormone releasing peptides. In: Bercu B.B., Walker R.F. (Eds.), Growh hormone II, basic and clinical aspects. Springer-Verlag, New York, 1993, p. 203.
17. Bowers C.Y., Reynolds G.A., Durham D., Barrera C.M., Pezzoli S.S., Thorner M.O. Growth hormone (GH)-releasing peptide stimulates GH release in normal men and acts synergistically with GH-releasing hormone. Clin. Endocrinol. Metab. 70: 975, 1990.
18. Penalva A., Carballo A., Pombo M., Casanueva F.F., Dieguez C. Effect of growth hormone (GH)-releasing hormone (GHRH), atropine, pyridostigmine, or hypoglycemia on GHRP-6-induced GH secretion in man. Clin. Endocrinol. Metab. 76: 168, 1993.
19. Ghigo E., Arvat E., Gianotti L., lmbimbo B.P., Lenaerts V., Deghenghi R., Camanni F. Growth hormone-releasing activity of Hexarelin, a new synthetic hexapeptide, after intravenous, subcutaneous, intranasal and oral administration in man. Clin. Endocrinol. Metab. 78: 693, 1994.
20. Arvat E., Gianotti L., Di Vito L., lmbimbo B.P., Lenaerts V., Deghenghi R., Camanni F., Ghigo E. Modulation of growth hormone-releasing activity of hexarelin in man. Neuroendocrinology 61: 51, 1995.
21. Smith R.G., Cheng K., Pong S.S., Hickey G., Jacks T., Butler B., Chan W.W., Chaung L.Y.P., Judith F., Taylor F.J., Wyvratt M.J., Fisher M.H. A non-peptidyl GH secretagogue. Science 260: 1640, 1993.
22. Jacks T., Hickey G., Judith F., Taylor J., Chen H., Krupa D., Feeney W., Schoen W., Ok D., Fisher M., Wyvratt M., Smith R. Effects of acute and repeated intravenous administration of L-692,585, a novel non-peptidyl growth hormone secretagogue, on plasma growth hormone, IGF-I, ACTH, cortisol, prolactin, insulin, and thyroxine levels in beagles. J. Endocrinol. 143: 399, 1994.
23. Chang C.H., Rickes E.L., Marsilio F., McGuire L., Cosgrove S., Taylor J, Chen S., Feighner S., Clark J.N., De Vita R., Schoen W., Wyvratt M., Fisher M., Smith R.G., Mickey G.J. Activity of a novel non peptidyl GH secretagogue, L-700,653, in swine. Endocrinology 136: 1065, 1995.
24. Hickey G.J., Jacks T., Judith F., Taylor J., Schoen W.R., Krupa D., Cunningham P., Clark J., Smith R.G. Efficacy and specificity of L-692,429, a novel non-peptidyl growth hormone secretagogue, in beagles. Endocrinology 134: 695, 1994.
25. Gertz B.J., Barrett J.S., Eisenhandler R., Krupa D.A., Wittreich J.M., Seibold J.R., Schneider S.H. Growth hormone response in man to L-692,429, a novel non peptide mimic of growth hormone-releasing peptide-6. J. Clin. Endocrinol. Metab. 77: 1393, 1993.
26. Imbimbo B.P., Mant T., Edward M., Amin D., Froud A., Lenaerts V, Boutignon F., Deghenghi R. Growth hormone-releasing activity of hexarelin in humans: a dose-response study. Eur.J. Clin.Pharrnacol. 46: 421, 1994.
27. Korbonits M., Trainer P.J., Besser G.M. The effect of an opiate antagonist on the hormonal changes induced by hexarelin. Clin. Endocrinol. (Oxf.) 43: 365, 1995.
28. Copinschi G., van Ondergen A., L'hermite-Baleriaux M., Mendel C.M., Caufriez A., Leproult R., Thorner M.O. Effects of 7-day treatment with a novel, orally active, growth hormone (GH) secretagogue, MK-677, on 24-hour GH profiles, insulin-like growth factor I, and adrenocortical function in normal young men. J. Clin. Endocrinol. Metab. 81: 2776, 1996.
29. Deghenghi R., Boutignon F., Wuthrich P., Lenaerts V., Imbimbo B., Lucchelli P.E., Locatelli V., Battisti C., Cananzi M., Müller E.E. GH releasing properties of hexarelin (EP 23905). International Symposium on Growth Hormone II: Basic and Clinical Aspects, Tarpon Springs, Florida, p. 31 (Abstract), 1992.
30. Muccioli G., Ghè C., Ghigo M.C., Arvat E., Papotti M., Boghen M.F., Deghenghi R., Ong H., Ghigo E. Presence of specific receptors for Hexarelin, a GH releasing hexapeptide, in human brain and pituitary gland. International symposium Growth Factors in Endocrinology and Metabolism, Berlin, p. 110 (Abstract), 1995.
31. Goodman and Gilman's. The pharmacological basis of therapeutics, ed 7. Macmillan Publ. Comp., New York, 1975.
32. Massara F., Ghigo E., Demislis K., Tangolo D., Mazza E., Locatelli V., Müller E.E., Camanni F. Cholinergic involvement in the growth hormone releasing hormone-induced growth hormone release. Studies in normal and acromegalic subjects. Neuroendocrinology 43: 670, 1986.
33. Maccario M., Arvat E., Procopio M., Gianotti L., Grottoli S., Imbimbo B.P., Lenaerts V., Deghenghi R., Camanni F. Metabolic modulation of the growth-hormone-releasing activity of hexarelin in man. Metabolism 44: 134, 1995.